Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics

Rhea-AI Filing Summary

Eventide Asset Management, LLC and two affiliated individuals report a significant ownership position in Ovid Therapeutics Inc. As of June 30, 2026, Eventide, as investment adviser to the Eventide Healthcare & Life Sciences Fund, is the beneficial owner of 11,812,241 shares of Ovid’s common stock, representing 6.3% of the outstanding shares.

Eventide holds sole voting and dispositive power over these 11,812,241 shares, while Finny Kuruvilla, M.D., Ph.D. and Robin C. John have shared voting and dispositive power over the same amount. All three reporting parties jointly file this Schedule 13G/A and expressly disclaim beneficial ownership of the securities beyond what is attributable under applicable rules.

Key Figures

Shares beneficially owned: 11,812,241 shares Percent of class: 6.3% Sole voting power: 11,812,241 shares +3 more

6 metrics

Shares beneficially owned 11,812,241 shares Beneficially owned by Eventide Asset Management, LLC as of June 30, 2026

Percent of class 6.3% Percentage of Ovid’s outstanding common stock represented by 11,812,241 shares

Sole voting power 11,812,241 shares Shares over which Eventide has sole power to vote or direct the vote

Shared voting power 11,812,241 shares Shares over which Kuruvilla and John each have shared voting power

Sole dispositive power 11,812,241 shares Shares over which Eventide has sole power to dispose or direct disposition

Shared dispositive power 11,812,241 shares Shares over which Kuruvilla and John each have shared dispositive power

Key Terms

beneficial owner, sole voting power, shared dispositive power, registered investment company, +2 more

6 terms

beneficial owner regulatory

"is the beneficial owner of 11,812,241 shares of the Issuer's Common Stock"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

sole voting power regulatory

"Sole Voting Power 11,812,241.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power regulatory

"Shared Dispositive Power 11,812,241.00"

registered investment company financial

"which is a registered investment company"

A registered investment company is a pooled investment vehicle—such as a mutual fund or closed-end fund—that is officially registered with financial regulators and required to follow rules about disclosure, how it invests, and what fees it charges. Think of it as a shared basket of stocks or bonds managed for many investors; registration means regular reporting and oversight that help investors compare costs, understand risks, and know how easy it is to buy or sell their shares.

Rule 13d-4 regulatory

"In accordance with Rule 13d-4 of the Securities Exchange Act of 1934"

Schedule 13G regulatory

"to file a Statement on relating to their ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What ownership stake in Ovid Therapeutics (OVID) does Eventide report?

Eventide reports beneficial ownership of 11,812,241 shares of Ovid Therapeutics common stock, representing 6.3% of the company’s outstanding common stock as of June 30, 2026, through the Eventide Healthcare & Life Sciences Fund.

Who are the reporting persons in this OVID Schedule 13G/A amendment?

The reporting persons are Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John, who jointly file regarding their beneficial ownership of Ovid Therapeutics’ common stock as of June 30, 2026.

How many OVID shares does the Eventide Healthcare & Life Sciences Fund hold?

The Eventide Healthcare & Life Sciences Fund held 11,812,241 shares of Ovid Therapeutics common stock as of June 30, 2026, which equates to 6.3% of Ovid’s outstanding common stock according to the filing.

What voting and dispositive powers are reported over OVID shares?

Eventide has sole voting and sole dispositive power over 11,812,241 OVID shares. Finny Kuruvilla and Robin C. John each have shared voting and shared dispositive power over the same 11,812,241 shares, with no sole power reported.

Do the reporting persons claim full beneficial ownership of their OVID position?

No. The reporting persons expressly disclaim beneficial ownership of the securities covered, stating that the filing should not be construed as an admission that they are the beneficial owners under Rule 13d-4 of the Exchange Act.

What is the key date referenced in this OVID Schedule 13G/A filing?

The key reference date is June 30, 2026, as of which the reporting persons state that 11,812,241 Ovid Therapeutics shares, or 6.3% of the outstanding common stock, were held by the Eventide Healthcare & Life Sciences Fund.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 11:42 AM Accepted by SEC EDGAR 08/14/2026 - 11:41 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Ovid Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

690469101

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 690469101

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,812,241.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,812,241.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,812,241.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 690469101

1

Names of Reporting Persons

Finny Kuruvilla, M.D., Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 11,812,241.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,812,241.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,812,241.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 690469101

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 11,812,241.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,812,241.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,812,241.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ovid Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 441 Ninth Avenue, 14th floor, New York, NY 10001
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 690469101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 11,812,241 (ii) Kuruvilla: 11,812,241 (iii) John: 11,812,241
(b)	Percent of class: (i) Eventide: 6.3% (ii) Kuruvilla: 6.3% (iii) John: 6.3%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 11,812,241 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 11,812,241 (3) John: 11,812,241
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 11,812,241 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 11,812,241 (3) John: 11,812,241
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. As of June 30, 2026, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 11,812,241 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Healthcare & Life Sciences Fund which is a registered investment company. As of June 30, 2026, the Eventide Healthcare & Life Sciences Fund held 11,812,241 shares of the Issuer's Common Stock, representing 6.3% of the Issuer's outstanding Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	08/14/2026

Finny Kuruvilla, M.D., Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	08/14/2026

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	08/14/2026

Exhibit Information

EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: August 14, 2026 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title: General Counsel Finny Kuruvilla, M.D., Ph. D. Date: August 14, 2026 By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Robin C. John Date: August 14, 2026 By: /s/ Robin C. John Name: Robin C. John